All In Biotech

Free tool

FAERS Monitor: Dantrium

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 018264 or its brand name (Dantrium, Dantrolene Sodium). Reports on generic versions are filed under their own applications.

Reports

1,138

Serious

998

88% of reports

Hospitalization

547

Death reported

124

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • neuroleptic malignant syndrome79
  • pyrexia63
  • pneumonia61
  • asthenia59
  • drug ineffective59
  • respiratory failure59
  • off label use54
  • urinary tract infection52
  • vomiting52
  • diarrhoea49
  • muscular weakness45
  • nausea45
  • convulsion41
  • fatigue41
  • hypertension35

Reports by year received

View as table
YearReports
200445
200547
200654
200749
200859
200962
201061
201181
201283
201373
201443
201546
201663
201757
201845
201953
202042
202131
202236
202335
202427
202530
202616

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,021 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
neuroleptic malignant syndromeSignal79123.9100.19,453
respiratory failureSignal5915.011.7757
convulsionSignal4113.39.8453
muscular weaknessSignal457.35.5240
urinary tract infectionSignal525.64.3195
pneumoniaSignal613.52.7107
pyrexiaSignal633.42.6104
hypertensionSignal353.12.247
astheniaSignal592.92.373
vomitingSignal522.01.627
diarrhoea491.41.15
off label use541.10.91
nausea451.10.80
fatigue411.00.70
drug ineffective590.80.62

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.